Subcutaneous Injection of Erythropoietin on Visual Functions in Patients With Late Onset Optic Neuropathy
- Registration Number
- NCT04469777
- Lead Sponsor
- Alexandria University
- Brief Summary
This study aimed to investigate the therapeutic effect of subcutaneous erythropoietin in the management of late stage optic neuropathy.
- Detailed Description
Injury of the optic nerve or optic neuropathy is one of the most common causes of vision loss. This study aimed to investigate the therapeutic effect of subcutaneous erythropoietin in the management of late stage optic neuropathy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Patients with late stage optic neuropathy (1 month to 12 months after onset of optic neuropathy due to late referral of the cases)
Exclusion Criteria
- Patients with perforating ocular injuries were excluded.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Systemic erythropoietin injections erythropoietin 20 patients diagnosed as late onset optic neuropathy that were attending Alexandria main university hospital.Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
- Primary Outcome Measures
Name Time Method Assessment of visual acuity 3 months Visual acuity using appropriate charts for assessment then convert into log of the minimum angle of resolution (logMAR) units to provide a numeric scale of visual acuity
Flash visual-evoked potentials 3 months Flash VEP to detect amplitude reduction and latency in the optic nerve.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Alexandria Faculty of Medicine
🇪🇬Alexandria, Egypt